Please provide your email address to receive an email when new articles are posted on . There are four scenarios in which patients with HCC and extrahepatic disease (EHD) should be considered for ...
A minimally invasive treatment that delivers cancer-killing radiation directly to tumors shows promise in treating breast cancer that has spread to the liver when no other treatment options remain.
To study the impact of transarterial Yttrium-90 radioembolization (TARE) in combination with second-line systemic chemotherapy for colorectal liver metastases (CLM). In this international, multicenter ...
March 29, 2012 (Orlando, Florida) — Results of the largest study to date assessing the efficacy of radioembolization with yttrium-90 microspheres in the treatment of unresectable hepatic tumors have ...
Survival of patients treated with SIR-Spheres more than double that of patients who received best supportive care, benefit rivals that found with new biological agents, authors note The results of a ...
Analysis revealed survival for patients with hepatocellular carcinoma (HCC) is achievable using 90Y-resin microsphere radioembolization. The analysis conducted at multiple centers across Europe showed ...
Bleeding events and eligibility requirements in studies evaluating an antiangiogenic agent in hepatocellular carcinoma (HCC). Background: Few effective treatments exist for unresectable hepatic ...
The majority of patients with advanced colorectal cancer die from hepatic metastases caused by disease progression; therefore, several novel technologies are in clinical development to potentially ...
A team of physicians from the Baylor College of Medicine and the Texas Children’s Cancer Center’s Pediatric Liver Tumor Program have begun using a state-of-the-art treatment known as transarterial ...
Radioembolization is a generally painless procedure for liver cancer that directly targets the blood supply to the tumor site. Approximately 70% to 95% of patients will experience improvements in ...
WESTMINSTER, Colo., April 23, 2014 /PRNewswire/ -- Surefire Medical, Inc. announced that a symposium focused on the Coiling vs. Surefire Infusion System in Y90 (COSY) clinical trial will be held ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results